Vanguard Advisers Inc
BVS icon

Vanguard Advisers Inc’s Bioventus BVS Stock Holding History

Vanguard Advisers Inc’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53
Closed -$484 – 726
2026
Q1 		$484 Buy
+53
New +$444 ﹤0.01% 594

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Advisers Inc's BVS Position: Q2 2026 in Review

Vanguard Advisers Inc sold out of Bioventus (BVS) in Q2 2026, closing a stake of 53 shares — an estimated $484 sold.

Vanguard Advisers Inc first reported a position in BVS in Q1 2026 and held it in 1 quarter. The position peaked at $484 in Q1 2026. 155 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Vanguard Advisers Inc reported no remaining Bioventus position as of Q2 2026 after selling out during the quarter.
  • Vanguard Advisers Inc sold 53 Bioventus shares in Q2 2026, an estimated $484.
  • Vanguard Advisers Inc first reported a position in Bioventus in Q1 2026 and held it in 1 quarter.
  • Vanguard Advisers Inc's Bioventus position peaked at $484 in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Vanguard Advisers Inc's 13F filing for Q2 2026, filed 13 Aug 2026.